Auxly Cannabis Group Inc. (XLY.TO) Investment Analysis
1. Executive Summary
Auxly Cannabis Group Inc. operates as a vertically integrated consumer packaged goods company in the Canadian legal cannabis market, focusing on the cultivation, processing, product development, and distribution of raw flower and derivative cannabis products for the recreational adult-use, wellness, and medical markets.[1, 2] The company generates its commercial revenues primarily through the sale of branded cannabis products to provincial control boards and authorized distributors across Canada, with a footprint in all ten provinces and two territories.[1, 3] Domestic operations are heavily concentrated in the major markets of Ontario, Alberta, and British Columbia, which combined account for approximately 71% to 74% of the company's total cannabis sales.[3, 4] Additionally, the company participates in business-to-business wholesale bulk cannabis transactions with other licensed producers (LPs) to optimize inventory levels and is actively developing direct international wholesale channels to address emerging medical cannabis opportunities in Europe.[1, 3]
The core product portfolio is bifurcated into Dried Flower & Pre-rolls (accounting for approximately 69% of net revenue) and Cannabis 2.0 & Derivative products (accounting for the remaining 31% of net revenue).[4] Product brands are structured to address distinct consumer segments, ensuring broad market coverage [3, 4]:
| Brand |
Product Category Focus |
Consumer Market Segment |
Core Value Proposition |
Source |
| Back Forty |
Flower, Pre-rolls, Vaporizers |
Value adult-use consumer |
High THC, consistent quality, competitive price |
[5, 6] |
| South Point |
Dried Flower |
Premium tier adult-use consumer |
High-quality, premium aesthetics and genetics |
[7] |
| Kolab Project |
Specialty Pre-rolls, Vapes, Concentrates |
Connoisseur / Craft adult-use |
Specialized genetics, artisanal craft quality |
[3, 4] |
| Foray |
Vaporizers, Edibles |
Accessible wellness and lifestyle |
Standardized dosing, entry-level accessibility |
[3, 4] |
| Parcel |
Dried Flower |
Ultra-value / Economy consumer |
Maximum volume, highly accessible price point |
[3, 4] |
| Dosecann |
Formulated Oils |
Medical and wellness consumer |
Science-backed, standardized medical solutions |
[3, 4] |
Auxly's primary customer types are the state-sanctioned provincial monopoly wholesalers—such as the Ontario Cannabis Store (OCS), the British Columbia Liquor Distribution Branch (BCLDB), and the Alberta Gaming, Liquor and Cannabis Commission (AGLC)—which act as the primary gatekeepers to the retail store network.[1, 3, 8] The company also serves authorized medical patients directly through dedicated digital medical portals.[1, 9]
Recreational retail consumers choose Auxly over competing brands due to its value-for-money proposition, specifically under the Back Forty label.[5, 10] This brand has established itself by delivering high-THC profiles and product consistency at a competitive retail price.[5] This positioning is enabled by Auxly's large-scale automated cultivation and specialized manufacturing capabilities, which minimize product defects and yield high-throughput volumes.[11]
2. Business Drivers & Strategic Overview
Commercial Infrastructure and Revenue Drivers
The primary revenue drivers for Auxly include sales volumes in its core dried flower and pre-roll segments, the commercialization of high-potency derivative formats (such as disposable "All-in-One" vaporizers), and the expansion of wholesale and international export channels.[3, 4, 5, 10] Strategically, the company relies on its manufacturing footprint to achieve structural advantages [9, 11]:
- Auxly Leamington (Ontario): This 1.1 million-square-foot automated greenhouse facility operates as the agricultural hub of the organization.[12, 13] The facility is equipped with computerized environmental controls, supplemental lighting, and automated irrigation systems to ensure consistent biomass quality.[11] It produces over 100,000 kilograms of cannabis annually, generating a cash cost-per-gram approximately 30% to 40% below typical indoor cultivation peers, which supports the company's value-brand pricing strategy.[9, 11]
- Auxly Charlottetown (Prince Edward Island): Operating as a 52,000-square-foot downstream manufacturing hub, this facility handles extraction, sensory testing, and packaging for vaporizer and oil portfolios.[11, 12] A five-year partnership with a major global tobacco equipment manufacturer allows the company to optimize its high-speed pre-roll and vape production lines, keeping product failure and return rates low.[11]
Moat Analysis
Auxly's competitive advantages are driven by cultivation scale, brand equity, and distribution depth.[7, 9, 11] The company does not possess a high switching-cost moat among retail end-users, but it has built key barriers to entry:
- Cost Advantage via Automation: The Leamington greenhouse allows the company to produce at low cost-per-gram rates.[9, 13] Smaller, boutique craft producers cannot compete at these unit economics, which helps Auxly maintain price competitiveness in the value segment.[5, 9]
- Brand Equity: The Back Forty brand was the #1 cannabis brand in Canada throughout 2025.[7] This consumer brand recognition drives consistent shelf velocity, making it an essential listing for retailers.[5, 14]
- Distribution Footprint: Auxly has secured distribution in approximately 97% of all Canadian retail stores across all ten provinces and two territories, a level of retail shelf dominance that is difficult for new entrants to replicate.[3, 11]
- Intellectual Property and Strategic Partnerships: The company's proprietary genetics library and customized extraction formulations are supported by its manufacturing agreements, which help maintain product consistency and enhance margins.[9, 11, 13]
Total Addressable Market (TAM) & Industry Dynamics
The Canadian legal cannabis industry reached approximately CAD 5.42 billion in retail sales in 2025, serving 7.1 million past-year consumers.[8] The legal market is projected to expand at a 5.5% CAGR to hit CAD 7.10 billion by 2030, driven by the ongoing transition of consumers from the illicit market to regulated retail channels.[8]
| Canadian Province / Territory |
2025 Legal Retail Sales (CAD) |
YoY Growth (%) |
Retail Outlets |
Source |
| Ontario |
\$2.19 Billion |
+5.0% |
1,855 |
[8] |
| Quebec |
\$890 Million |
+7.0% |
107 |
[8] |
| Alberta |
\$808 Million |
+2.0% |
766 |
[8] |
| British Columbia |
\$712 Million |
+4.0% |
486 |
[8] |
| Saskatchewan |
\$272 Million |
+3.0% |
185 |
[8] |
| Manitoba |
\$192 Million |
+3.0% |
200 |
[8] |
| Nova Scotia |
\$117 Million |
+4.0% |
41 |
[8] |
| New Brunswick |
\$102 Million |
+6.0% |
28 |
[8] |
| Newfoundland & Labrador |
\$68 Million |
+3.0% |
43 |
[8] |
| Prince Edward Island |
\$25 Million |
+3.0% |
4 |
[8] |
| Yukon |
\$21 Million |
+4.0% |
9 |
[8] |
Within the product landscape, a major structural shift occurred in 2025: pre-rolls overtook dried flower to become the single largest product category in the Canadian legal market, reaching CAD 1.43 billion in annual sales.[6] Within this segment, multi-packs (especially 1.5g, 2.5g, and 3.5g formats) dominate consumer demand, accounting for 86.7% of all pre-roll unit sales in Canada.[6] This product category shift plays directly to Auxly's automated pre-roll manufacturing capabilities.[6, 11]
Concurrently, the European medical cannabis market is expanding.[15, 16] Germany imported a record 201 tonnes of medical cannabis in 2025 (+176% year-over-year) and crossed EUR 1 billion in pharmacy sales, driven by the liberalizing impact of the CanG act.[16] Because Canadian producers supply roughly 50% of Germany’s imports, Auxly's Leamington facility—which holds GACP export certification—is strategically positioned to capture high-margin international wholesale demand as it scales its export channels.[3, 11, 17]
Competitive Landscape and Market Positioning
The Canadian market is highly fragmented, with no single licensed producer commanding more than a 25% share.[15] Auxly is currently positioned as the #3 Canadian Licensed Producer by total recreational retail market share.[1, 7]
The company's flagship brand, Back Forty, held the spot of #1 cannabis brand in Canada by total dollar sales throughout 2025 and into early 2026.[5, 7] Auxly is gaining ground in the dried flower and pre-roll segments.[4, 10] The launch of South Point and Backpackers pre-rolls has allowed the company to defend its market share against value-focused competitors.[4, 11, 14] Conversely, in the vape category, Auxly is holding ground amidst aggressive price compression by prioritizing the higher-margin, proprietary "Boosted" all-in-one disposable formats.[5, 10, 14]
Key competitors include Tilray, Canopy Growth, Organigram, and Decibel.[10, 15, 16] Auxly’s 22% year-over-year net revenue growth in Q1 2026 outpaced the broader Canadian cannabis market’s growth rate of approximately 2%, indicating that the company is actively gaining market share from other LPs.[5]
3. Financial Performance & Valuation
Latest Quarterly Financial Results (Q1 2026)
On May 14, 2026, Auxly reported its financial results for the first quarter ended March 31, 2026.[18, 19] The performance highlighted strong organic growth and significant operating leverage.[20]
- Net Revenue: Net revenue reached CAD 39.8 million, up 22% year-over-year compared to CAD 32.7 million in Q1 2025.[10] This outpaced the broader Canadian cannabis market’s seasonal growth rate of just 2% over the same period.[5] The revenue gain was driven by higher sales volumes of dried flower and pre-rolls, improved pricing in the flower portfolio, and expanded retail distribution.[4, 10] This performance beat analyst expectations of CAD 36.0 million by approximately 10.72%.[21]
- Earnings Per Share (EPS) and Net Income: Diluted EPS was CAD 0.00, which met consensus analyst expectations of CAD 0.00.[1, 5, 21] Net income recorded was CAD 3.5 million, down from CAD 12.1 million in Q1 2025.[10] However, the Q1 2025 results included a non-recurring CAD 8.1 million deferred tax recovery.[10] Excluding fair value adjustments on biological assets and non-recurring tax items, net income increased by CAD 5.8 million year-over-year, driven by improved gross profits and reduced interest expenses.[10]
- Adjusted EBITDA: Adjusted EBITDA grew 65% year-over-year to CAD 12.3 million (representing an Adjusted EBITDA margin of 31%, compared to 23% in Q1 2025).[10, 11] This marks Auxly's 11th consecutive quarter of positive Adjusted EBITDA.[11]
- Cash Flow & Balance Sheet: Cash flow from operations before working capital changes grew 102% year-over-year to CAD 11.3 million, representing a 92% cash conversion rate from Adjusted EBITDA.[10] The company finished Q1 2026 with CAD 42.7 million in cash, up from CAD 32.3 million at the end of fiscal 2025.[10]
Revenue and Margin Performance
| Financial Metric (CAD in Thousands) |
Q1 2026 |
Q1 2025 |
YoY % Change |
Source |
| Gross Cannabis Sales |
\$59,738 |
\$49,212 |
+21.4% |
[1, 10] |
| Excise Taxes |
(\$19,985) |
(\$16,543) |
+20.8% |
[1, 10] |
| Net Revenue |
\$39,753 |
\$32,669 |
+21.7% |
[1, 10] |
| Gross Margin on Finished Inventory Sold |
55.0% |
48.0% |
+7.0 ppt |
[1, 10] |
| Selling, General & Administrative (SG&A) |
\$11,384 |
\$9,672 |
+17.7% |
[1, 10] |
| Adjusted EBITDA |
\$12,256 |
\$7,433 |
+64.9% |
[1, 10] |
| Net Income |
\$3,466 |
\$12,111 |
-71.4% |
[1, 10] |
Balance Sheet Restructuring and Capital Changes
Auxly's financial turnaround is supported by a comprehensive balance sheet restructuring.[14, 22] Historically, the company was burdened by a CAD 123 million convertible debenture held by Imperial Brands PLC.[23, 24]
In April 2024, Imperial converted CAD 123.4 million of principal and accrued interest into common shares, acquiring a 19.8% equity stake.[23, 25] In July 2025, Auxly closed a final debt settlement with Imperial.[22, 26] Under this agreement, Imperial converted its remaining CAD 1.0 million principal and CAD 1.39 million of accrued interest into common shares, and accepted pre-funded warrants for CAD 7.37 million of interest.[22, 26] The remaining CAD 11.79 million of accrued interest was forgiven, leaving Auxly with zero debt obligations to Imperial Brands, while Imperial maintained a 19.9% equity stake.[22]
Concurrently, in July 2025, Auxly amended and extended its syndicated credit facility led by the Bank of Montreal (BMO).[22, 26] The outstanding debt was structured into a CAD 50.7 million facility, consisting of a CAD 36.2 million term loan, a CAD 10.0 million revolving facility, and CAD 4.5 million in equipment leases.[22, 26] As of March 31, 2026, the outstanding balance under this credit facility was reduced to CAD 42.2 million.[1] These debt reduction initiatives halved quarterly interest and accretion expenses from CAD 2.1 million in Q1 2025 to CAD 1.1 million in Q1 2026.[1, 10] This deleveraging brought Auxly's Total Debt-to-TTM Adjusted EBITDA ratio down to a highly conservative 0.9x.[10, 11]
Capital Allocation Strategy
The company's improved cash generation has shifted its capital allocation strategy toward shareholder returns and selective organic growth.[20]
* Share Repurchase Program (NCIB): In April 2026, Auxly launched a Normal Course Issuer Bid (NCIB) to buy back and cancel up to 68.9 million common shares (representing roughly 4.9% of its public float) through April 19, 2027.[27]
* Capital Expenditures: For fiscal 2026, management plans to allocate between CAD 10.0 million and CAD 12.0 million of operating cash flow toward capital projects at the Auxly Leamington greenhouse.[4] These projects aim to expand cultivation yields, improve automated packaging throughput, and prepare the facility for direct international shipments.[28]
* Share Consolidation: At the Annual General Meeting (AGM) on June 30, 2026, shareholders approved a special resolution granting the Board of Directors authorization to execute a share consolidation at a ratio of up to 20-to-1.[29, 30] This consolidation is intended to elevate the nominal share price, broadening Auxly's eligibility for institutional investment funds and large brokerage platforms.[20]
Guidance and Consensus Analyst Estimates
During the Q1 2026 earnings announcement, management maintained its previously issued guidance for fiscal year 2026.[5] The company expects to continue growing net revenues above broader market rates, while sustaining positive operating cash flows and strong EBITDA margins.[5, 20]
The market response to the Q1 2026 earnings report was neutral, with the stock price remaining steady in the CAD 0.14 to CAD 0.18 range.[5, 21] Analyst recommendations remain positive, with a consensus "Strong Buy" rating among covering analysts.[31, 32] The average 12-month consensus price target stands at CAD 0.25 to CAD 0.26, representing an estimated upside of approximately 42.9% from the current share price of CAD 0.18.[21, 31, 33]
4. Risk Assessment & Macroeconomic Considerations
Company-Specific Execution Risks
- Biological Transformation Volatility: Cultivation at the 1.1 million-square-foot Leamington facility exposes Auxly to agricultural risks, including potential crop disease, pest infestations, and localized climate control failures.[12, 13] Under IFRS accounting standards, the company must regularly revalue its biological assets.[1, 10] As seen in Q1 2026, fluctuations in the fair value of biological assets can introduce significant volatility into GAAP net income, even when underlying cash EBITDA remains stable.[10]
- Greenhouse Optimization and Yield Targets: The planned CAD 10.0 million to CAD 12.0 million capital expenditure program for 2026 is intended to improve throughput and quality at Leamington.[4] If these optimization projects face construction delays or fail to deliver the anticipated yield improvements, the company's ability to maintain its low-cost structure could be compromised.[9]
Competitive & Pricing Risks
- Persistent Vape and Flower Price Compression: The Canadian cannabis sector is characterized by continuous price compression, driven by overproduction and retail discounting.[5, 34] Average prices per gram fell by 2.5% year-over-year as of April 2026.[34] Although Auxly has managed to expand its gross margins through cultivation efficiencies, ongoing price declines in vaporizers could erode its gross profits if cost-saving initiatives reach their practical limits.[5, 10]
- Aggressive Competitor Brand Launches: Value-brand competitors, such as General Admission and Shred, continuously refresh their product lines.[6] Auxly must sustain high levels of marketing support and product innovation to prevent its flagship Back Forty brand from losing shelf-space dominance.[7, 14]
Customer Concentration and Demand Risks
- Provincial Monopsony Exposure: Auxly is highly dependent on a small number of provincial cannabis boards, with approximately 74% of fiscal 2025 sales concentrated in Ontario, Alberta, and British Columbia.[3] These government-run distributors have substantial bargaining power.[1, 8] Any decision by a major provincial board to reduce inventory levels, adjust product listing criteria, or impose higher markups would directly impact Auxly's top-line revenue.[1, 3]
Regulatory and Legal Risks
- High Excise Taxation Burden: The Canadian regulatory framework imposes a heavy excise tax on adult-use cannabis products, typically structured as the greater of CAD 1.00 per gram or 10% of the wholesale price.[4] In Q1 2026, Auxly paid CAD 20.0 million in excise taxes on CAD 59.7 million in gross sales, representing a 33.5% tax rate on gross revenues.[1, 4] This high tax burden limits net margin expansion and leaves LPs with narrow operational buffers.[1, 4]
- Stricter Marketing and Packaging Restrictions: Under the federal Cannabis Act, cannabis packaging must be plain and feature prominent health warnings. This limits the company's ability to build brand equity through traditional CPG marketing channels, making consumer loyalty highly dependent on pricing and product consistency.[1, 5]
Balance Sheet & Industry Structure Risks
- Refinancing Risk on Senior Debt: While the July 2025 refinancing extended the maturity of the BMO syndicated credit facility, the outstanding CAD 42.2 million balance must eventually be refinanced or repaid from free cash flows.[1] A return to a high-interest-rate environment could increase debt service costs when the facility is renewed.[22, 26]
- Liquidity Pressure and Industry Insolvencies: The Canadian cannabis industry continues to see high numbers of insolvencies, such as Ayurcann Holdings Corp. entering CCAA creditor protection in early 2026.[15, 35] While consolidations can reduce overall industry capacity, they can also lead to discounted inventory liquidation, which temporarily depresses wholesale prices.[35, 36]
Macroeconomic Sensitivities
- Discretionary Spending Pressures: While cannabis has shown relatively inelastic demand characteristics, prolonged macroeconomic pressure or inflation could cause consumers to trade down from premium brands like South Point to lower-margin value formats like Parcel, shifting the product mix toward lower gross profit margins.[4, 7]
Risk Matrix Framework
To help visualize these risks, the table below outlines key risk scenarios, their potential early warning signs, and their ultimate impact on the long-term investment thesis:
| Risk Category |
What Could Go Wrong |
Early Warning Sign |
Impact on Long-Term Thesis |
| Execution |
Crop failure or yield loss at the Leamington greenhouse.[13] |
Increasing inventory impairment charges in quarterly filings.[1] |
Damages the low-cost producer status, raising cash cost-per-gram.[9] |
| Competitive |
Deepening price compression in the core vaporizer segment.[5] |
Sequential declines in gross margins for Finished Cannabis Inventory.[10] |
Compromises operating cash flow generation and delays deleveraging.[14] |
| Regulatory |
Continued high excise tax rates or new municipal restrictions.[4] |
Excise taxes exceeding 35% of gross revenues.[1, 4] |
Permanently depresses net profit margins and limits equity valuation.[1] |
| Capital Allocation |
Refinancing difficulties for the BMO syndicated credit facility.[22] |
Rising debt service ratios or breach of financial covenants.[1] |
Restricts free cash flow, halts the NCIB, and increases dilution risk.[20, 27] |
5. 5-Year Scenario Analysis
This scenario analysis projects Auxly's potential valuation and share price outcomes over a five-year horizon (FY 2031).[21, 31] The projections are based on the company's Q1 2026 trailing twelve months (TTM) net revenue of CAD 158.6 million and its current outstanding share count of 1,405,038,794.[11, 21, 27]
The model uses pre-consolidation share counts for comparability with the current share price of CAD 0.18.[21, 31] A subsequent 20-to-1 share consolidation would scale the nominal prices and targets proportionally by a factor of 20, leaving the fundamental investment returns and percentage changes identical.[20, 29]
Projections and Mathematical Valuation Bridges
1. Base Case (55% Probability): Steady Domestic Expansion and Export Growth
- Revenue Assumption: Assumes an 8.0% CAGR over the next five years, driven by steady domestic demand, pre-roll segment growth, and moderate international export volumes.[4, 8, 33] Year 5 Net Revenue is projected at CAD 233.0 million.
- EBITDA & Earnings Margin: Assumes the Adjusted EBITDA margin stabilizes at 30.0%.[10, 11] Year 5 EBITDA is projected at CAD 69.9 million. The net income margin is projected at 15.0%, yielding CAD 35.0 million in earnings.[10]
- Share Count: Assumes the company repurchases and cancels shares via its NCIB, resulting in a net 10.0% reduction in outstanding shares to 1.26 billion.[20, 27]
- Valuation Multiple: Assumes an EV/EBITDA multiple of 7.0x and a P/E multiple of 14.0x.[31, 37]
- Valuation Bridge:
$\text{EV} = \text{EBITDA} \times \text{Multiple} = \text{CAD } 69.9\text{M} \times 7 = \text{CAD } 489.3\text{M}$
Subtracting projected net debt of CAD 10.0 million (reflecting cash accumulation offsetting the BMO credit facility balance) yields an equity value of CAD 479.3 million.[1, 10]
$\text{Implied Share Price} = \frac{\text{CAD } 479.3\text{M}}{1.26\text{B shares}} \approx \text{CAD } 0.38$
Alternatively, applying a 14.0x P/E multiple to CAD 35.0 million in net income yields an equity value of CAD 490.0 million, supporting a projected target of CAD 0.38 to CAD 0.39.[31, 37]
2. High Case (25% Probability): Accelerating International Exports and Portfolio Premiumization
- Revenue Assumption: Assumes a 12.0% CAGR, driven by accelerating medical exports to Germany and the European Union, alongside successful market share gains in the premium domestic flower segment via the South Point brand.[7, 11, 17] Year 5 Net Revenue is projected at CAD 279.5 million.
- EBITDA & Earnings Margin: Assumes the Adjusted EBITDA margin expands to 33.0% due to the higher-margin export mix, yielding Year 5 EBITDA of CAD 92.2 million.[10, 17] Net income margin is projected at 18.0%, yielding net income of CAD 50.3 million.[10]
- Share Count: Assumes aggressive FCF generation allows the company to reduce its share count by 18.1%, down to 1.15 billion shares.[20, 27]
- Valuation Multiple: Assumes a higher EV/EBITDA multiple of 9.0x and a P/E multiple of 17.0x, reflecting reduced regulatory risks and a higher-margin international revenue mix.[31, 37]
- Valuation Bridge:
$\text{EV} = \text{CAD } 92.2\text{M} \times 9 = \text{CAD } 829.8\text{M}$
Adding projected net cash of CAD 40.0 million yields an equity value of CAD 869.8 million.[10, 11]
$\text{Implied Share Price} = \frac{\text{CAD } 869.8\text{M}}{1.15\text{B shares}} \approx \text{CAD } 0.76$
Applying a 17.0x P/E multiple to CAD 50.3 million in earnings yields an equity value of CAD 855.1 million, supporting a share price target of CAD 0.74 to CAD 0.76.[37]
3. Low Case (20% Probability): Price Compression and Flat Revenue Growth
- Revenue Assumption: Assumes a 2.0% CAGR, reflecting severe domestic price compression and a failure to establish international export channels.[3, 5, 34] Year 5 Net Revenue is projected at CAD 175.1 million.
- EBITDA & Earnings Margin: Assumes intense price competition compresses the Adjusted EBITDA margin to 20.0%, yielding Year 5 EBITDA of CAD 35.0 million.[5, 10] Net margin declines to 5.0%, yielding CAD 8.8 million in net earnings.[10]
- Share Count: Assumes share repurchases are halted and stock-based compensation causes slight dilution, raising the share count to 1.40 billion.[1, 27]
- Valuation Multiple: Assumes valuation multiples contract to 5.0x EV/EBITDA and 10.0x P/E due to slower growth.[31, 37]
- Valuation Bridge:
$\text{EV} = \text{CAD } 35.0\text{M} \times 5 = \text{CAD } 175.0\text{M}$
Subtracting projected net debt of CAD 35.0 million yields an equity value of CAD 140.0 million.[1, 10]
$\text{Implied Share Price} = \frac{\text{CAD } 140.0\text{M}}{1.40\text{B shares}} \approx \text{CAD } 0.10$
This supports a projected share price of CAD 0.10.[37]
Five-Year Scenario Matrix
| Scenario |
Revenue / key scale metric in Year 5 |
Margin / earnings assumption |
Valuation multiple assumption |
Current share price |
Implied future share price |
5-year total return |
Annualized return |
Probability |
| High Case |
CAD 279.5 Million |
33.0% EBITDA / 18.0% Net |
9.0x EV/EBITDA / 17.0x P/E |
CAD 0.18 |
CAD 0.75 |
+316.7% |
+33.0% |
25% |
| Base Case |
CAD 233.0 Million |
30.0% EBITDA / 15.0% Net |
7.0x EV/EBITDA / 14.0x P/E |
CAD 0.18 |
CAD 0.38 |
+111.1% |
+16.1% |
55% |
| Low Case |
CAD 175.1 Million |
20.0% EBITDA / 5.0% Net |
5.0x EV/EBITDA / 10.0x P/E |
CAD 0.18 |
CAD 0.10 |
-44.4% |
-11.0% |
20% |
Using these probability weights, the mathematically derived, probability-weighted share price target for Auxly Cannabis Group Inc. over a five-year horizon is:
$\text{Weighted Price Target} = (0.25 \times \text{CAD } 0.75) + (0.55 \times \text{CAD } 0.38) + (0.20 \times \text{CAD } 0.10) \approx \text{CAD } 0.42$
This probability-weighted target of CAD 0.42 represents a significant potential premium over the current market price of CAD 0.18, reflecting the company's improved balance sheet and operational turnaround.[21, 22, 31]
ASYMMETRIC RETURN PROSPECT
6. Qualitative Scorecard
This qualitative scorecard evaluates Auxly Cannabis Group Inc. across ten operational and financial dimensions, utilizing a rating scale of 1 to 10 (with 10 indicating exceptional strength and 1 representing severe weakness):
1. Management Alignment: 8/10
Co-founder and CEO Hugo Alves has led the executive team since August 2019, bringing deep sector experience and operational continuity.[38, 39] Alves directly holds 3.7% of the outstanding common shares, representing an equity stake valued at over CAD 9.29 million.[39] Furthermore, Alves and CFO Travis Wong have been active buyers of Auxly stock on the open market, indicating insider confidence.[39] However, CEO compensation remains somewhat elevated relative to the company's micro-cap peers, though it remains aligned with recent earnings improvements.[38, 39]
2. Revenue Quality: 7/10
Auxly's revenues are supported by popular consumer brands, with Back Forty holding the spot of #1 brand in Canada throughout 2025.[7] However, revenue quality is slightly affected by geographic concentration, as approximately 71% of cannabis sales originate from British Columbia, Alberta, and Ontario.[4] Additionally, the legal market remains exposed to wholesale pricing fluctuations and potential regulatory interventions by provincial monopsonies.[1, 3]
3. Market Position: 8/10
The company is positioned as the #3 Licensed Producer by total retail market share in Canada, holding a strong competitive position in a highly fragmented market.[1, 7, 15] Its products are carried in approximately 97% of all retail dispensaries across Canada, giving the company substantial distribution scale and retail shelf presence.[11]
4. Growth Outlook: 7/10
While the domestic Canadian recreational market is mature, Auxly has growth opportunities in the pre-roll category, which has become Canada's largest product segment.[6, 8] Additionally, the company is building high-margin international export channels to target the rapidly expanding German and European medical cannabis markets.[3, 4, 17]
5. Financial Health: 8/10
Auxly's balance sheet has improved significantly.[5, 14] The settlement of the CAD 123 million Imperial Brands convertible debenture in 2025 eliminated a major debt overhang and substantially reduced annual interest and accretion expenses.[22, 23, 25] With its Total Debt-to-TTM Adjusted EBITDA ratio at 0.9x and a cash balance of CAD 42.7 million, Auxly is in its strongest financial position in several years.[10, 11]
6. Business Viability: 8/10
The company's vertical integration model is anchored by the 1.1 million-square-foot Leamington greenhouse and the specialized PEI manufacturing facility, which provide a durable operational structure.[11, 12, 40] This large-scale, automated infrastructure yields cash costs that are 30% to 40% below indoor peers, helping to protect the business against ongoing industry price compression.[9]
7. Capital Allocation: 7/10
Management has demonstrated improved capital discipline, as shown by its decision to remain firm on its valuation threshold and walk away from bidding up the Ayurcann assets.[20, 36] Capital is currently being directed toward high-return projects at the Leamington greenhouse, alongside share repurchases under the active NCIB.[4, 20, 27] However, the history of high equity dilution continues to weigh on the capital structure.[23, 41]
8. Analyst Sentiment: 6/10
Because of its history of financial challenges and its current penny-stock status, Auxly has limited coverage from major institutional analysts.[37, 42] However, the few analysts covering the stock maintain a consensus "Strong Buy" recommendation, with an average 12-month price target of CAD 0.25 to CAD 0.26, representing substantial estimated upside.[21, 31, 32, 33]
9. Profitability: 8/10
Auxly delivers strong profitability metrics, with a gross margin of 55% on finished inventory and an Adjusted EBITDA margin of 31% in Q1 2026.[10] The company has achieved 11 consecutive quarters of positive Adjusted EBITDA, reflecting solid operational execution and cost management.[11]
10. Track Record: 4/10
Auxly has a history of significant wealth destruction for early shareholders, driven by extensive equity dilution and high interest expenses from previous debt facilities.[41, 43] While current management has successfully executed a financial turnaround over the past two years, the historical share price performance remains a weak point for the company's track record.[22, 43]
Blended Qualitative Score: 7.1 / 10
The blended qualitative score of 7.1 out of 10 reflects a business that has successfully executed an operational and financial turnaround.[14, 22] While historical dilution and a mature domestic market remain headwind factors, the company’s low-cost cultivation scale, strong brand equity, and improved balance sheet position it well relative to its Canadian peers.[5, 9, 22]
TRANSFORMING PENNY STOCK
7. Conclusion & Investment Thesis
The core investment thesis for Auxly Cannabis Group Inc. is built on its transition from a highly leveraged, speculative cultivator into a profitable, cash-generating CPG operator.[14, 22] For several years, the company was held back by the CAD 123 million convertible debenture held by Imperial Brands.[23, 24] The full conversion and settlement of this debt in 2025 significantly improved the balance sheet, eliminating the interest expense overhang and reducing the Total Debt-to-TTM Adjusted EBITDA leverage ratio to an efficient 0.9x.[10, 22]
Key Investment Catalysts
- Pre-roll Automation and Category Dominance: As pre-rolled joints have become the largest product category in the Canadian legal market, Auxly's automated pre-roll manufacturing capabilities and its partnership with a leading global tobacco equipment manufacturer should help it capture high-margin market share.[6, 11]
- High-Margin International Medical Exports: The company's GACP-certified Leamington facility is positioned to begin direct exports to Germany and the European Union, capitalizing on rapid medical market growth and capturing pricing premiums over the domestic Canadian wholesale market.[3, 11, 17]
- NCIB and Share Consolidation: The active NCIB to buy back up to 4.9% of outstanding common shares, combined with the shareholder-approved 20-to-1 share consolidation, is expected to help reduce equity overhang, elevate the nominal share price, and attract institutional investment capital.[20, 27, 29]
Key Investment Risks
- Ongoing Price Compression: Continued price compression in the Canadian adult-use market remains a key risk, which could compress gross margins if cost-saving initiatives at the Leamington greenhouse reach their practical limits.[5, 10, 34]
- High Excise Taxes: The Canadian excise tax regime continues to place a heavy burden on operating cash flows, consuming over 33% of gross revenues and limiting net income expansion.[1, 4]
- Customer Concentration: Sales remain highly concentrated among three provincial control boards, exposing the company to inventory adjustments or listing changes by these government distributors.[1, 3]
In summary, while the Canadian cannabis sector faces structural and regulatory challenges, Auxly's low-cost cultivation scale, strong brand positioning, and improved balance sheet suggest that the company is currently valued at a discount relative to its financial turnaround and cash-generation capabilities.[5, 9, 22, 37]
STRIKING ASYMMETRIC RECOVERY
8. Technical Analysis, Price Action & Short-Term Outlook
Auxly’s stock price has shown positive medium-term momentum, trading at CAD 0.18, which is 21.99% higher than its 200-day simple moving average of CAD 0.14.[31, 44] This upward trend is supported by a bullish golden cross that occurred on June 16, 2026, when the 50-day moving average crossed above the 200-day moving average.[45, 46] In the short term, technical indicators suggest a period of consolidation, as the stochastic oscillator is currently in the overbought zone and the daily price has dipped slightly below its 50-day moving average of CAD 0.18.[46, 47] The short-term outlook remains constructive, with key support holding at the CAD 0.15 level, while the market continues to evaluate the timing of the board’s planned 20-to-1 share consolidation and subsequent share repurchases under the NCIB.[20, 27, 29]
BULLISH STRUCTURAL REBOUND
- Auxly Cannabis Group Inc. Management's Discussion and Analysis ..., https://www.auxly.com/wp-content/themes/auxly-site-production/media/2026Q1/2026.03.31_Q1_2026_MDA.pdf
- XLY - Auxly Cannabis Group Inc. (TSX) - Share Price and News - Fintel, https://fintel.io/s/ca/xly
- Auxly reports net revenue up 24% in 2025, earmarks up to $12m for 2026 capital projects, https://stratcann.com/financials/auxly-reports-net-revenue-up-24-in-2025-earmarks-up-to-12m-for-2026-capital-projects/
- Auxly's Revenue Up in Q1 2026, Driven by Flower and Pre-Roll ..., https://stratcann.com/financials/auxly-q1-2026/
- Earnings call transcript: Auxly Cannabis Q1 2026 sees record revenue growth, https://www.investing.com/news/transcripts/earnings-call-transcript-auxly-cannabis-q1-2026-sees-record-revenue-growth-93CH-4689134
- Pre-Rolls Now Lead Canada's Cannabis Market. What Comes Next? | StratCann, https://stratcann.com/news/pre-rolls-now-lead-canadas-cannabis-market/
- Auxly Reports Fourth Quarter and Full Year 2025 Results, https://www.auxly.com/news/auxly-reports-fourth-quarter-and-full-year-2025-results/
- Canadian Cannabis Statistics 2026 — Market Size, Sales, Provinces, https://cannabispromotions.com/stats/canada/
- Auxly: Business Model Canvas – MatrixBCG.com, https://matrixbcg.com/products/auxly-business-model-canvas
- Auxly Reports First Quarter 2026 Results, https://www.auxly.com/news/auxly-reports-first-quarter-2026-results/
- This is Auxly Corporate Presentation - Auxly Cannabis Group, https://www.auxly.com/wp-content/themes/auxly-site-production/media/corporate_presentation/XLY_Corp_Presentation_Q1_2026.pdf
- Auxly Charlottetown - PEI BioAlliance, https://peibioalliance.com/company/dosecann/
- Auxly Acquires 100% Ownership of Sunens and Amends Credit Facility, https://www.auxly.com/2021/11/
- This is Auxly / Q4 2025 Shareholder Letter, https://docs.publicnow.com/viewDoc.aspx?filename=74496\EXT\C23769CA44E8211240D0B20A9D79DEA7E5161C20_2FC1348229EB8CDBC2F4840CA67166BEFD6C4F0C.PDF
- Consolidation Wave Reshapes Global Cannabis — February 2026 - Cannamonitor, https://cannamonitor.com/consolidation-wave-reshapes-global-cannabis-february-2026/
- Germany Imports 201 Tonnes of Medical Cannabis in 2025 and Crosses €1 Billion in Sales, https://cannamonitor.com/germany-imports-201-tonnes-of-medical-cannabis-in-2025/
- Who Supplies Germany's Medical Cannabis in 2026? - Ziel, https://www.ziel.com/press/who-supplies-germanys-medical-cannabis-in-2026/
- Investors - This is Auxly., https://www.auxly.com/investors/
- Auxly Announces Results of Annual General and Special Meeting of Shareholders, https://auxly.com/category/news/
- Q1 2026 results - Auxly Cannabis Group, https://www.auxly.com/wp-content/themes/auxly-site-production/media/2026Q1/2026.03.31_Q1_2026_LetterToShareHolders.pdf
- Auxly Cannabis Group Inc Stock Price Today | TSX: XLY Live - Investing.com, https://www.investing.com/equities/knightswood-financial-corp
- Auxly Closes Transformational Debt Reduction Transactions, Strengthens Financial Position and Unlocks Growth Potential - PR Newswire, https://www.prnewswire.com/news-releases/auxly-closes-transformational-debt-reduction-transactions-strengthens-financial-position-and-unlocks-growth-potential-302499670.html
- Imperial Brands Sticks with Auxly but Takes Big Hit - New Cannabis Ventures, https://www.newcannabisventures.com/imperial-brands-sticks-with-auxly-but-takes-big-hit/
- IMPERIAL BRANDS PLC EXTENDS $123 MILLION CONVERTIBLE DEBENTURE AND AUXLY IMPLEMENTS BOARD AND MANAGEMENT CHANGES - Canada Newswire, https://www.newswire.ca/news-releases/imperial-brands-plc-extends-123-million-convertible-debenture-and-auxly-implements-board-and-management-changes-871603565.html
- AUXLY ANNOUNCES COMPLETION OF CONVERSION OF OVER $123 MILLION OF PRINCIPAL ANDINTEREST UNDER IMPERIAL DEBENTURE, https://www.auxly.com/news/auxly-announces-completion-of-conversion-of-over-123-million-of-principal-andinterest-under-imperial-debenture/
- Auxly Closes Transformational Debt Reduction Transactions, Strengthens Financial Position and Unlocks Growth Potential, https://www.auxly.com/2025/07/
- Auxly Announces Normal Course Issuer Bid - PR Newswire, https://www.prnewswire.com/news-releases/auxly-announces-normal-course-issuer-bid-302740906.html
- Auxly Reports First Quarter 2026 Results – Company Announcement - Markets data, https://markets.ft.com/data/announce/detail?dockey=600-202605140745CANADANWCANADAPR_C1229-1
- Auxly Announces Results of Annual General and Special Meeting of Shareholders, https://www.auxly.com/news/auxly-announces-results-of-annual-general-and-special-meeting-of-shareholders-4/
- Press Release: Auxly Announces Results of Annual General and Special Meeting of Shareholders - Moomoo, https://www.moomoo.com/news/post/72397616/press-release-auxly-announces-results-of-annual-general-and-special
- Auxly Cannabis Share Price, Forecast & Financials (TSE:XLY) - Stockopedia, https://www.stockopedia.com/share-prices/auxly-cannabis-TSE:XLY/
- Auxly Cannabis (XLY) Stock Forecast & Price Target - Investing.com, https://www.investing.com/equities/knightswood-financial-corp-consensus-estimates
- XLY Stock Forecast - Auxly Cannabis Group Inc - Alpha Spread, https://www.alphaspread.com/security/tsx/xly/analyst-estimates
- April 2026 Cannabis Sales Data: Regional Trends and National Growth | StratCann, https://stratcann.com/news/april-2026-cannabis-sales-data-regional-trends-and-national-growth/
- Auxly's stalking horse bid for Ayurcann not selected, named back-up bidder - StratCann, https://stratcann.com/news/auxlys-stalking-horse-bid-for-ayurcann-not-selected-named-back-up-bidder/
- Auxly Provides Update on Stalking Horse Bid for Ayurcann, https://auxly.com/news/auxly-provides-update-on-stalking-horse-bid-for-ayurcann/
- Auxly Cannabis Group (TSX:XLY) Stock Valuation, Peer Comparison & Price Targets, https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsx-xly/auxly-cannabis-group-shares/valuation
- Auxly Cannabis Group Inc. (CBWT.F) Leadership & Management Team Analysis, https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-cbwt.f/auxly-cannabis-group/management
- Auxly Cannabis Group Inc. (XLY) Leadership & Management Team Analysis, https://simplywall.st/stocks/ca/pharmaceuticals-biotech/tsx-xly/auxly-cannabis-group-shares/management
- Auxly Announces Cultivation Optimization Plan and Related Cost Savings Initiatives, https://www.auxly.com/news/auxly-announces-cultivation-optimization-plan-and-related-cost-savings-initiatives/
- Auxly Cannabis is a double over the next year, says Raymond James - Cantech Letter, https://www.cantechletter.com/2020/08/auxly-cannabis-is-a-double-over-the-next-year-says-raymond-james/
- Auxly Cannabis Group Inc. Price: Quote, Forecast, Charts & News (XLY.TO) - Perplexity, https://www.perplexity.ai/finance/XLY.TO
- Auxly Cannabis Group Inc. (3KF) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/de/pharmaceuticals-biotech/fra-3kf/auxly-cannabis-group-shares/management
- XLY.TO Technical Analysis for Auxly Cannabis Group Stock - Barchart.com, https://www.barchart.com/stocks/quotes/XLY.TO/technical-analysis
- State Street Consumer Discretionary Select Sector SPDR ETF (XLY) Analysis - Tickeron, https://tickeron.com/ticker/XLY/
- State Street® CnsmrDiscSelSectSPDR®ETF (XLY) Stocks News Today - Tickeron.com, https://tickeron.com/ticker/XLY/signals/
- XLY Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/knightswood-financial-corp-technical